Drug Profile
Vedolizumab - Takeda Oncology
Alternative Names: ENTYVIO; Entyvio; Kynteles; LDP-02; LPD-02; MLN-0002; MLN-002; MLN02Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Medical College of Wisconsin; Millennium; Takeda; Takeda Oncology
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Crohn's disease; Ulcerative colitis
- Registered Pouchitis
- Phase III Graft-versus-host disease
- Phase II Coeliac disease
- No development reported Malignant melanoma
Most Recent Events
- 05 Feb 2024 Takeda plans a phase III VICTRIVA trial for Crohn's Disease (Monotherapy, Combination therapy, Treatment-experienced) in July 2024 (IV) (NCT06227910)
- 14 Oct 2023 Efficacy and adverse event data from an extended access programme in Ulcerative Colitis and Crohn's Disease presented at the 31st United European Gastroenterology Week (UEGW-2023)
- 30 Sep 2023 Registered for Crohn's disease (In the elderly, In adults) in Japan, USA (SC) (Takeda pipeline, November 2023)